Celldex Therapeutics, Inc. (CLDX:NASDAQ) closed at $31.24 on November 9, 2026, up 4.59% on the day. The stock trades 30.8% below its 52-week high of $45.14 and 41.4% above its 52-week low of $22.10. Over the past year, it gained 37.8%. Celldex Therapeutics, Inc. is part of the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances).
In 252 trading sessions since November 7, 2025, CLDX closed higher on 125 days (50%). Its best day was February 25, 2026 (+24.07%) and its worst was September 22, 2026 (-11.56%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 1 time.
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in p...
Find more stocks like CLDX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.